Integrated cervical cancer screening in Mayuge District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol

Carolyn Nakisige, Jessica Trawin, Sheona Mitchell-Foster, Beth A Payne, Angeli Rawat, Nadia Mithani, Cathy Amuge, Heather Pedersen, Jackson Orem, Laurie Smith, Gina Ogilvie, Carolyn Nakisige, Jessica Trawin, Sheona Mitchell-Foster, Beth A Payne, Angeli Rawat, Nadia Mithani, Cathy Amuge, Heather Pedersen, Jackson Orem, Laurie Smith, Gina Ogilvie

Abstract

Background: Cervical cancer is almost entirely preventable through vaccination and screening, yet remains one of the 'gravest threats to women's lives' according to the World Health Organization. Specific high-risk subtypes of human papillomavirus (HR-HPV) are well-established as the primary cause of cervical cancer. Uganda has one of the highest cervical cancer incidence rates in the world (54.8 per 100,000) as a result of limited screening access and infrastructure. The integration of a self-collected cervical cancer screening program using HPV testing within existing community-based primary health care services could increase access to screening and reduce cervical cancer rates among Ugandan women.

Methods: Using a pragmatic, sequential, cluster randomized trial design; we will compare the effectiveness of two cervical cancer screening models for self-collected HPV testing: 1) community health worker recruitment (door-to-door); and 2) community health meetings. In Mayuge district, Uganda, 31 villages are randomized to one of two treatment arms. Due to the nature of this trial, blinding is not possible. Women are eligible to participate if they have no previous history of hysterectomy or treatment for cervical cancer or pre-cancer and are aged 25-49 years old. All participants receive an integrated package of cervical cancer screening and education. Samples are tested for HPV using GeneXpert point of care testing. All women who test positive for HR-HPV types are referred to a designated health centre for follow-up inspection by Visual Inspection with Acetic acid (VIA) and treatment with thermal ablation. The primary outcome for the trial is the number of women who attend follow-up for VIA screening at a designated Health Centre after a positive HR-HPV test out of all women screened per arm. Secondary outcomes include: cervical cancer screening knowledge; patient-reported experience measures for self-collected cervical cancer screening; and HPV incidence.

Discussion: Results from this study will inform the national scale-up of cervical cancer screening in Uganda, aligning with the World Health Organization's target of achieving cervical cancer elimination through the pillar of increased HPV screening coverage.

Trial registration: ISRCTN, ISRCTN12767014. Registered 14 May 2019, https://doi.org/10.1186/ISRCTN12767014; clinicaltrials.gov, NCT04000503; Registered 27 June 2019, https://ichgcp.net/clinical-trials-registry/NCT04000503 PROTOCOL VERSION: January 8, 2020, version 1.

Keywords: Cervical cancer; Cervical cancer screening; Developing countries; Global health; Human papillomavirus; Human papillomavirus DNA tests; Low resource setting; Self-collection; Visual inspection with acetic acid.

Conflict of interest statement

No competing interests.

Figures

Fig. 1
Fig. 1
Recruitment flow
Fig. 2
Fig. 2
Pathways to Care Diagram. Legend describes who is involved in each step of the process
Fig. 3
Fig. 3
Logic Model

References

    1. World Health Organization. Draft: Global strategy towards the elimination of cervical cancer as a public health problem. Geneva, Switzerland; 2019.
    1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I BF. Global Cancer Observatory: Cervix Uteri Fact Sheet [Internet]. Lyon, France: International Agency for Research on Cancer; 2018 . Available from: [cited 2019 5 Sep]
    1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I BF. Global Cancer Observatory: Uganda Fact Sheet [Internet]. Lyon, France: International Agency for Research on Cancer; 2018 [cited 2019 Sep 5]. Available from:
    1. Black E, Hyslop F, Richmond R. Barriers and facilitators to uptake of cervical cancer screening among women in Uganda: a systematic review. BMC Womens Health. 2019;19(1):108. doi: 10.1186/s12905-019-0809-z.
    1. Nakisige C, Schwartz M, Ndira AO. Cervical cancer screening and treatment in Uganda. Gynecol Oncol Rep. 2017;20:37–40. doi: 10.1016/j.gore.2017.01.009.
    1. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial Neoplasia. JAMA. 2001;286(24):3106–3114. doi: 10.1001/jama.286.24.3106.
    1. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the young women’s health study. J Infect Dis. 2002;186(4):462–469. doi: 10.1086/341782.
    1. World Health Organization. Comprehensive cervical cancer control: a guide to essential practice. Geneva: World Health Organization; 2014.
    1. Woodman CBJ, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831–1836. doi: 10.1016/S0140-6736(00)04956-4.
    1. Adebamowo SN, Olawande O, Famooto A, Dareng EO, Offiong R, Adebamowo CA, et al. Persistent low-risk and high-risk human papillomavirus infections of the uterine cervix in HIV-negative and HIV-positive women. Front Public Heal. 2017;5:178. doi: 10.3389/fpubh.2017.00178.
    1. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva, Switzerland; 2013.
    1. Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob Heal. 2019;4(3):e001351. doi: 10.1136/bmjgh-2018-001351.
    1. Ogilvie G, Krajden M, Maginley J, Isaac-Renton J, Hislop G, Elwood-Martin R, et al. Feasibility of self-collection of specimens for human papillomavirus testing in hard-to-reach women. CMAJ. 2007;177(5):480. doi: 10.1503/cmaj.070013.
    1. Safaeian Mahboobeh E, Kiddugavu Mohammed J, Gravitt Patti V, Ssekasanvu Joseph V, Murokora Dan V, Sklar Marc V, et al. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai. Uganda Sex Transm Dis. 2007;34(7):429–436. doi: 10.1097/01.olq.0000243623.67673.22.
    1. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011;378(9806):1868. doi: 10.1016/S0140-6736(11)61522-5.
    1. World Health Organization. Task shifting: rational redistribution of tasks among health workforce teams: global recommendations and guidelines. Geneva, Switzerland; 2008.
    1. O’Donovan J, O’Donovan C, Nagraj S. The role of community health workers in cervical cancer screening in low-income and middle-income countries: a systematic scoping review of the literature. BMJ Glob Heal. 2019;4(3):e001452. doi: 10.1136/bmjgh-2019-001452.
    1. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–1327. doi: 10.2105/AJPH.89.9.1322.
    1. Mayuge District Local Government. District Development Plann II (2015/2016–2019/2020) [Internet]. 2015. Available from: [cited 2019 Sep 19].
    1. World Health Organization. Cervical cancer screening and management of cervical pre-cancers: training of community health workers. Regional Office for South-East Asia: World Health Organization; 2017.
    1. Michie S, Richardson M, Johnston M, Arbraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Ann Behav Med. 2013;46(1):81–95. doi: 10.1007/s12160-013-9486-6.
    1. Toliman P, Badman SG, Gabuzzi J, Silim S, Forereme L, Kumbia A, et al. Field evaluation of Xpert HPV point-of-care test for detection of human papillomavirus infection by use of self-collected vaginal and clinician-collected cervical specimens. Diekema DJ, editor. J Clin Microbiol. 2016 Jul 1;54(7):1734 LP-1731737.
    1. Berer M. Integration of sexual and reproductive health services: a health sector priority. Reprod Health Matters. 2003;11(21):6–15. doi: 10.1016/S0968-8080(03)02179-7.
    1. World Health Organization. Improving data for decision-making: a toolkit for cervical cancer prevention and control programmes. Geneva, Switzerland; 2016.
    1. Fujisawa R, Klazinga N. Measuring patient experiences (PREMS): Progress made by the OECD and its member countries between 2006 and 2016. OECD Health Working Papers. Paris; 2017. Report No.: 102.
    1. Mukama T, Ndejjo R, Musabyimana A, Halage AA, Musoke D. Women’s knowledge and attitudes towards cervical cancer prevention: a cross sectional study in eastern Uganda. BMC Womens Health. 2017;17(1):9. doi: 10.1186/s12905-017-0365-3.
    1. Patridge EF, Bardyn TP. Research Electronic Data Capture (REDCap). J Med Libr Assoc. 2018/01/02. 2018 Jan;106(1):142–144.
    1. Kleinman K, Moyer J, Reich N, Obeng D. clusterPower: power calculations for cluster-randomized and cluster-randomized crossover trials. 2017.
    1. Uganda Ministry of Health. Strategic Plan for Cervical Cancer Prevention and Control in Uganda [Internet]. 2010. Available from: [cited 2019 Sep 19]
    1. Ndejjo R, Mukama T, Musabyimana A, Musoke D. Uptake of cervical cancer screening and associated factors among women in rural Uganda: a cross sectional study. PLoS One. 2016;11(2):e0149696. doi: 10.1371/journal.pone.0149696.
    1. Stern E, Pascoe L, Shand T, Richmond S. Lessons learned from engaging men in sexual and reproductive health as clients, partners and advocates of change in the Hoima district of Uganda. Cult Health Sex. 2015;17(sup2):190–205. doi: 10.1080/13691058.2015.1027878.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere